Al's Comment:

 This is a new approach that targets the tumor microenvironment.  See their website for details!  This trial is early, but has very impressive results in a bad patient population - those who have MGMT unmethylated.  90% of patients had tumors shrink, and 40% had a partial response. The median survival has not been reached yet as the patients are still alive after average follow up of 7.9 months.  There is a link to the poster presentation as well as a webinar they will be having about it soon, in the press release linked below!


Posted on: 11/19/2022

POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER PRESENTED AT THE SOCIETY FOR NEURO-ONCOLOGY 2022 ANNUAL MEETING

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click HERE to read it!